KRAS and acute lymphoblastic leukemia: Including all identified clonal, subclonal, and microclonal mutations, there were 43 HD-ALL patients (75.4%) with a damaging mutation in KRAS, NRAS, FLT3, and/or PTPN11, and 8 patients (14.0%) with a damaging CREBBP mutation (Figure 4).